**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

An adult man \[*age at reaction onset not stated*\] developed fatal coronavirus encephalitis during therapy with cyclophosphamide, fludarabine, antithymocyte globulin and alemtuzumab \[*routes and dosages not stated*\].

The man was diagnosed with acute lymphoblastic leukaemia (ALL) in December 2004 at the age of 30 years. Subsequently, he underwent chemotherapy following prophylactic CNS radiation therapy. Complete remission was achieved after alemtuzumab. Allogeneic stem cell transplantation (aSCT) was performed following a conditioning regimen, which included irradiation, fludarabine, antithymocyte globulin and post-SCT cyclophosphamide. During post transplant period, he developed reactivation of CMV and BK Virus-associated haemorrhagic cystitis as well as acute graft-versus-host disease. After discharge, he presented with progressive unconsciousness like catatonia along with apathy and generalised muscle weakness. Later, he fell into a coma and was artificially ventilated. In bronchoalveolar lavage Coronavirus was detected. His neurological symptoms persisted so another work up was performed. A MRI scan showed typical signs of encephalitis. Coronavirus was also found in cerebrospinal fluid. He was diagnosed with Coronavirus-associated encephalitis \[*durations of treatments to reactions onset not stated*\].

The man was started on treatment with foscarnet and immune globulins but his neurological symptoms accumulated with prolonged apnoea. So, he was again artificially ventilated, but he died due to respiratory paralysis.

**Author comment:** *\"Risk factors could be immunosuppression with alemtuzumab, \[antithymocyte globulin\], in vivo T-cell depletion with post-SCT cyclophosphamide, or the use of fludarabine for conditioning regimen as described in this case.\"*
